PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-96.92%
Negative revenue growth while ANO.AX stands at 59.92%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-102.97%
Negative gross profit growth while ANO.AX is at 20.34%. Joel Greenblatt would examine cost competitiveness or demand decline.
-144.64%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-144.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-113.30%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.90%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.00%
Negative OCF growth while ANO.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
22.84%
Positive FCF growth while ANO.AX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.32%
AR growth of 1.32% while ANO.AX is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.65%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-74.37%
We’re deleveraging while ANO.AX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
100.34%
R&D dropping or stable vs. ANO.AX's 1100.26%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-66.59%
We cut SG&A while ANO.AX invests at 78.49%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.